Shares of Juno Therapeutics, Inc. (NASDAQ:JUNO) have earned a consensus rating of “Hold” from the sixteen research firms that are presently covering the company, Marketbeat reports. Three analysts have rated the stock with a sell recommendation, six have assigned a hold recommendation and seven have assigned a buy recommendation to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $30.93.

A number of research analysts have recently commented on the stock. Vetr raised shares of Juno Therapeutics to a “buy” rating in a report on Tuesday, May 23rd. Zacks Investment Research cut shares of Juno Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday. Wedbush reissued a “neutral” rating and issued a $24.00 target price on shares of Juno Therapeutics in a report on Tuesday, June 6th. BidaskClub raised shares of Juno Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, June 20th. Finally, BTIG Research cut shares of Juno Therapeutics from a “neutral” rating to a “sell” rating and increased their target price for the stock from $12.00 to $23.00 in a report on Tuesday, June 6th.

ILLEGAL ACTIVITY NOTICE: This piece of content was posted by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark & copyright law. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/08/11/juno-therapeutics-inc-nasdaqjuno-given-average-rating-of-hold-by-brokerages.html.

In other news, Director Anthony B. Evnin bought 9,000 shares of the firm’s stock in a transaction on Tuesday, June 20th. The stock was acquired at an average price of $24.40 per share, with a total value of $219,600.00. Following the transaction, the director now owns 66,301 shares of the company’s stock, valued at approximately $1,617,744.40. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, major shareholder Douglas K. Bratton sold 8,000,000 shares of the stock in a transaction that occurred on Thursday, July 13th. The shares were sold at an average price of $27.00, for a total transaction of $216,000,000.00. The disclosure for this sale can be found here. Insiders sold 8,053,500 shares of company stock valued at $217,594,440 in the last ninety days. 15.26% of the stock is currently owned by insiders.

A number of hedge funds have recently added to or reduced their stakes in the stock. Amalgamated Bank increased its stake in Juno Therapeutics by 19.0% in the second quarter. Amalgamated Bank now owns 10,900 shares of the biopharmaceutical company’s stock worth $326,000 after buying an additional 1,741 shares in the last quarter. BlackRock Inc. increased its stake in Juno Therapeutics by 2.6% in the second quarter. BlackRock Inc. now owns 4,294,296 shares of the biopharmaceutical company’s stock worth $128,357,000 after buying an additional 110,503 shares in the last quarter. TIAA CREF Investment Management LLC increased its stake in Juno Therapeutics by 9.0% in the second quarter. TIAA CREF Investment Management LLC now owns 188,481 shares of the biopharmaceutical company’s stock worth $5,634,000 after buying an additional 15,491 shares in the last quarter. Teachers Advisors LLC increased its stake in Juno Therapeutics by 15.4% in the second quarter. Teachers Advisors LLC now owns 74,255 shares of the biopharmaceutical company’s stock worth $2,219,000 after buying an additional 9,890 shares in the last quarter. Finally, Leisure Capital Management purchased a new stake in Juno Therapeutics during the second quarter worth $255,000. 64.60% of the stock is owned by institutional investors and hedge funds.

Shares of Juno Therapeutics (NASDAQ:JUNO) opened at 27.97 on Friday. Juno Therapeutics has a 52-week low of $17.52 and a 52-week high of $35.04. The firm’s market cap is $2.93 billion. The firm has a 50-day moving average of $29.03 and a 200 day moving average of $24.53.

Juno Therapeutics (NASDAQ:JUNO) last posted its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.96) EPS for the quarter, missing analysts’ consensus estimates of ($0.72) by $0.24. The company had revenue of $21.30 million during the quarter, compared to the consensus estimate of $15.59 million. Juno Therapeutics had a negative return on equity of 27.10% and a negative net margin of 354.36%. The firm’s revenue was down 22.8% compared to the same quarter last year. During the same period last year, the company posted ($0.64) EPS. On average, equities analysts predict that Juno Therapeutics will post ($3.13) earnings per share for the current year.

Juno Therapeutics Company Profile

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

Analyst Recommendations for Juno Therapeutics (NASDAQ:JUNO)

Receive News & Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.